<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4749059</article-id><article-id pub-id-type="publisher-id">135</article-id><article-id pub-id-type="doi">10.1007/s10194-004-0135-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>An open label, randomised, pilot study of botulinum toxin type-A in the treatment of chronic tension-type headache</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Porta</surname><given-names>Mauro</given-names></name><address><phone>+39-035-886298</phone><fax>+39-035-885789</fax><email>prof.porta@inwind.it</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Maggioni</surname><given-names>Giorgio</given-names></name><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Via Legnano 14, Milan, Italy </aff><aff id="Aff2"><label/>Headache and Pain Center, Department of Neurology, Policlinico San Marco, Bergamo, Italy </aff><aff id="Aff3"><label/>Istituto Ortopedico Galeazzi, Milan, Italy </aff></contrib-group><pub-date pub-type="ppub"><month>12</month><year>2004</year></pub-date><volume>5</volume><issue>4</issue><fpage>251</fpage><lpage>255</lpage><history><date date-type="received"><day>23</day><month>12</month><year>2003</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2004</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag
Italia 2004</copyright-statement></permissions><abstract id="Abs1"><p>The objective was to assess the effect of botulinum toxin type-A (BTX-A) in treating chronic tension-type headache (CTTH). A single centre, open label, pilot study was carried out at the Headache and Pain Center, Neurology Department, Policlinico San Marco, Bergamo, Italy and the Istituto Ortopedico Galeazzi, Milan, Italy. Sixty consecutive patients meeting accepted criteria for CTTH were randomised into 3 equal groups. Group 1: patients injected in fixed points; Group 2: patients injected using the &#x0201c;follow the pain&#x0201d; approach; and Group 3: as per Group 2 but combined with physiotherapy. Patients were assessed for 4 months using a headache diary, and efficacy was evaluated using a verbal rating scale (VRS), changes in headache frequency and drug intake count. At month 3, all groups showed improvements in VRS, mean headache frequency and mean drug intake, with Group 3 showing the greatest improvements in VRS and drug intake. BTX-A may be a promising therapy for treatment of CTTH using the &#x0201c;follow the pain&#x0201d; approach, especially when combined with adjunctive physiotherapy.</p></abstract><kwd-group xml:lang="en"><title><bold>Key words</bold></title><kwd>Tension-type headache</kwd><kwd>Botulinum toxin type-A</kwd><kwd>Pain</kwd><kwd>Neuromuscular</kwd><kwd>Physiotherapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag
Italia 2004</meta-value></custom-meta></custom-meta-group></article-meta></front></article>